Abstract
Background
Studies have shown that potentially inappropriate prescribing (PIP) is highly prevalent among people with dementia (PwD) and linked to negative outcomes, such as hospitalisation and mortality. However, there are limited data on prescribing appropriateness for PwD in Saudi Arabia. Therefore, we aimed to estimate the prevalence of PIP and investigate associations between PIP and other patient characteristics among PwD in an ambulatory care setting.
Methods
A cross-sectional, retrospective analysis was conducted at a tertiary hospital in Saudi Arabia. Patients who were ≥ 65 years old, had dementia, and visited ambulatory care clinics between 01/01/2019 and 31/12/2021 were included. Prescribing appropriateness was evaluated by applying the Screening Tool of Older Persons Potentially Inappropriate Prescriptions (STOPP) criteria. Descriptive analyses were used to describe the study population. Prevalence of PIP and the prevalence per each STOPP criterion were calculated as a percentage of all eligible patients. Logistic regression analysis was used to investigate associations between PIP, polypharmacy, age and sex; odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Analyses were conducted using SPSS v27.
Results
A total of 287 PwD were identified; 56.0% (n = 161) were female. The mean number of medications prescribed was 9.0 [standard deviation (SD) ± 4.2]. The prevalence of PIP was 61.0% (n = 175). Common instances of PIP were drugs prescribed beyond the recommended duration (n = 90, 31.4%), drugs prescribed without an evidence-based clinical indication (n = 78, 27.2%), proton pump inhibitors (PPIs) for > 8 weeks (n = 75, 26.0%), and acetylcholinesterase inhibitors with concurrent drugs that reduce heart rate (n = 60, 21.0%). Polypharmacy was observed in 82.6% (n = 237) of patients and was strongly associated with PIP (adjusted OR 24.1, 95% CI 9.0–64.5).
Conclusions
Findings have revealed a high prevalence of PIP among PwD in Saudi Arabia that is strongly associated with polypharmacy. Future research should aim to explore key stakeholders’ experiences and perspectives of medicines management to optimise medication use for this vulnerable patient population.
Similar content being viewed by others
Background
Dementia is a progressive syndrome caused by underlying neurodegenerative processes and characterised by a decline from a previously attained cognitive level that affects memory, thinking, behaviour and activities of daily living [1]. The demographic shifting toward ageing populations is generating significant increases in dementia prevalence. In 2019, the number of people living with dementia worldwide was 55 million and this number is projected to increase to 139 million by 2050 [1]. In Saudi Arabia, there are no accurate national data about the prevalence of dementia, although Middle Eastern countries are predicted to have one of the highest dementia prevalence estimations in the world by 2050 [2]. Dementia is a leading cause of death globally, and it has been estimated that Alzheimer’s disease and other dementias are one of the leading causes of death for females in Saudi Arabia [3]. Increasing age is the strongest known risk factor for dementia, with the incidence doubling with every five-year increment in age [1]. Ageing is also combined with a gradual decline in physical function and a growing risk of multiple chronic conditions that usually require prescribing of multiple medications (polypharmacy) [4, 5].
Polypharmacy has been described using a numerical threshold, commonly four or five medications [6, 7]. Given the high prevalence of comorbid medical conditions and frailty among people with dementia (PwD), the risks of polypharmacy, drug-drug and drug-disease interactions are greater than among their older counterparts [8,9,10,11,12]. Polypharmacy may increase the possibility of adverse drug reactions, reduced medication adherence, and potentially inappropriate prescribing (PIP) [13]. PIP is the prescribing of medications where the risk of potential harm exceeds the potential benefit, and a safer option is available to treat the condition [14]. It has been linked to negative consequences in older adults such as adverse drug events, hospitalisation, mortality, and increased healthcare costs [15,16,17,18,56, 57]. A growing body of evidence has shown that successful deprescribing interventions were multidisciplinary in nature, with many including the provision of patient educational materials [58]. Currently, most of the medication optimisation and deprescribing interventions for PwD which are described in the literature are of poor quality, have multiple methodological limitations, have only targeted certain medication classes, have focused on medication-related outcomes instead of patient-centred outcomes, or been restricted to inpatients or those residing in long-term care facilities [59,60,61]. Future research should focus on the development and evaluation of complex, multidisciplinary and theory-based interventions for PwD that can be implemented in ambulatory care settings and cover multiple medications instead of specific medication classes [59, 61].
It is anticipated that the findings from this study will add to the limited evidence base that currently exists on appropriateness of prescribing for PwD in Saudi Arabia. In highlighting areas where prescribing may be considered potentially inappropriate, this should draw healthcare providers’ attention to this issue, particularly during clinical encounters with this patient population and when planning medication reconciliation and review activities. Healthcare providers’ attitudes and willingness towards improving prescribing and use of medications for PwD in Saudi Arabia should be explored in future research, along with the views of PwD and their caregivers in Saudi Arabia, as key partners in medication management.
Strengths and limitations
The present study has explored, for the first time, the prescribing patterns and appropriateness of prescribing for PwD in Saudi Arabia. The availability of medical diagnostic information and other clinical data through EHRs enabled us to apply a comprehensive set of STOPP criteria. However, it is important to consider the study’s limitations. Firstly, the STOPP criteria were assessed based on data extracted from EHRs, while medications prescribed by healthcare providers outside the hospital setting could not be captured. In addition, this study did not identify reports from participants’ family members or carers about patients’ self-medication, consider medications obtained without prescription (such as those bought over the counter), or medications prescribed “as needed”, which might have resulted in an underestimation of the prevalence of polypharmacy and PIP, especially for analgesic medications. Whilst the prevalence of prescribing of chronic NSAIDs was low in this study, a survey-based cross-sectional study using the Saudi National Survey for Elderly Health, which included around 3,000 Saudi older adults, reported that NSAIDs were used by 50% of the participants [62]. However, comparison is limited because PwD were not included in this survey. Moreover, other factors such as presence of comorbidities or recent hospitalisation, which may have had an impact on the prevalence of PIP, were not investigated in this study. We acknowledge some limitations to the approaches used to identify study participants– diagnostic codes may have been inaccurate and some patients with advanced dementia may not have been receiving a dementia medication. Whilst these may have resulted in an underestimation of the prevalence of people with dementia, we believe that using both of these approaches to identify study participants helped to mitigate the limitations of using one of these approaches in isolation. The use of electronic health records, such as those used in this study, is limited by the quality and volume of data recorded. The exclusion of those who died during the study period may have contributed to a survivor bias which may have affected the prevalence of PIP; however, we were limited by the data available to us from patients’ electronic records. Finally, the results are based on PwD who visited ambulatory care clinics of a single tertiary hospital in Riyadh; therefore, the findings may not be generalisable to all PwD across Saudi Arabia or different healthcare settings. Future work is needed to corroborate our findings across a more representative sample in Saudi Arabia. Tools such as the STOPP criteria are useful for both alerting healthcare providers to the use of potentially inappropriate medications and monitoring effectiveness for intervention-based studies that aimed to reduce PIP [63]. However, the use of such indicators of prescribing appropriateness should not replace clinical judgment and taking a person-centred approach to patient care.
Conclusion
Our findings have revealed a high prevalence of PIP that is strongly associated with polypharmacy among PwD in the ambulatory care setting. The perspectives of key stakeholders in medicines management including health care providers, PwD, and their carers in Saudi Arabia need to be explored in future research.
Data availability
The data are available from the corresponding author upon reasonable request.
Abbreviations
- ACB:
-
Anticholinergic burden
- ATC:
-
Anatomical therapeutic chemical classification
- BPSD:
-
Behavioural and psychological symptoms of dementia
- EHRs:
-
Electronic health records
- NSAID:
-
Non-steroidal anti-inflammatory drugs
- PIP:
-
Potentially inappropriate prescribing
- PPI:
-
Proton pump inhibitor
- PUD:
-
Peptic ulcer disease
- PwD:
-
People with dementia
- STOPP:
-
Screening Tool of Older Persons Potentially Inappropriate Prescriptions
- WHO:
-
World Health Organisation
References
World Health Organization. Dementia fact sheets, World Health Organization. 2022. Accessed 11 Jan 2023. https://www.who.int/news-room/fact-sheets/detail/dementia
Nichols E, Steinmetz JD, Vollset SE, Fukutaki K, Chalek J, Abd-Allah F, et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the global burden of disease study 2019. Lancet Public Health. 2022;7(2):e105–25. https://doi.org/10.1016/S2468-2667(21)00249-8
World Health Organization. Health data overview for the Kingdom of Saudi Arabia. 2019. Accessed 30 Nov 2023. https://data.who.int/countries/682
Topinková E. Aging, disability and frailty. Ann Nutr Metab. 2008;52:6–11. https://doi.org/10.1159/000115340
Marengoni A, Angleman S, Melis R, Mangialasche F, Karp A, Garmen A, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev. 2011;10(4):430–9. https://doi.org/10.1016/j.arr.2011.03.003
Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Waite L, Seibel MJ, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012;65(9):989–95. https://doi.org/10.1016/j.jclinepi.2012.02.018
Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230. https://doi.org/10.1186/s12877-017-0621-2
Bunn F, Burn A-M, Goodman C, Rait G, Norton S, Robinson L, et al. Comorbidity and dementia: a sco** review of the literature. BMC Med. 2014;12(1):192. https://doi.org/10.1186/s12916-014-0192-4
Browne J, Edwards DA, Rhodes KM, Brimicombe DJ, Payne RA. Association of comorbidity and health service usage among patients with dementia in the UK: a population-based study. BMJ Open. 2017;7(3):e012546. https://doi.org/10.1136/bmjopen-2016-012546
Clague F, Mercer SW, McLean G, Reynish E, Guthrie B. Comorbidity and polypharmacy in people with dementia: insights from a large, population-based cross-sectional analysis of primary care data. Age Ageing. 2017;46(1):33–9. https://doi.org/10.1093/ageing/afw176
Leelakanok N, D’Cunha RR. Association between polypharmacy and dementia - a systematic review and metaanalysis. Aging Ment Health. 2019;23(8):932–41. https://doi.org/10.1080/13607863.2018.1468411
Growdon ME, Gan S, Yaffe K, Steinman MA. Polypharmacy among older adults with dementia compared with those without dementia in the United States. J Am Geriatr Soc. 2021;69(9):2464–75. https://doi.org/10.1111/jgs.17291
Wastesson JW, Morin L, Tan ECK, Johnell K. An update on the clinical consequences of polypharmacy in older adults: a narrative review. Expert Opin Drug Saf. 2018;17(12):1185–96. https://doi.org/10.1080/14740338.2018.1546841
Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC. Explicit criteria for determining inappropriate medication use in nursing home residents. Ucla division of geriatric medicine. Arch Intern Med. 1991;151(9):1825–32.
Jano E, Aparasu RR. Healthcare outcomes associated with beers’ criteria: a systematic review. Ann Pharmacother. 2007;41(3):438–47. https://doi.org/10.1345/aph.1H473
Hill-Taylor B, Walsh KA, Stewart S, Hayden J, Byrne S, Sketris IS. Effectiveness of the Stopp/Start (screening tool of older persons’ potentially inappropriate prescriptions/screening tool to alert doctors to the right treatment) criteria: systematic review and meta-analysis of randomized controlled studies. J Clin Pharm Ther. 2016;41(2):158–69. https://doi.org/10.1111/jcpt.12372
Hyttinen V, Jyrkkä J, Valtonen H. A systematic review of the impact of potentially inappropriate medication on health care utilization and costs among older adults. Med Care. 2016;54(10):950–64. https://doi.org/10.1097/mlr.0000000000000587
Liew TM, Lee CS, Goh Shawn KL, Chang ZY. Potentially inappropriate prescribing among older persons: a meta-analysis of observational studies. Ann Fam Med. 2019;17(3):257–66. https://doi.org/10.1370/afm.2373
**ng XX, Zhu C, Liang HY, Wang K, Chu YQ, Zhao LB, et al. Associations between potentially inappropriate medications and adverse health outcomes in the elderly: a systematic review and meta-analysis. Ann Pharmacother. 2019;53(10):1005–19. https://doi.org/10.1177/1060028019853069
O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. Stopp/Start criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213–8. https://doi.org/10.1093/ageing/afu145
Arlt S, Lindner R, Rösler A, von Renteln-Kruse W. Adherence to medication in patients with dementia: predictors and strategies for improvement. Drugs Aging. 2008;25(12):1033–47. https://doi.org/10.2165/0002512-200825120-00005
El-Saifi N, Moyle W, Jones C, Tuffaha H. Medication adherence in older patients with dementia: a systematic literature review. J Pharm Pract. 2018;31(3):322–34. https://doi.org/10.1177/0897190017710524
Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. Front Neurol. 2012;3:73. https://doi.org/10.3389/fneur.2012.00073
Lyketsos CG, Carrillo MC, Ryan JM, Khachaturian AS, Trzepacz P, Amatniek J, et al. Neuropsychiatric symptoms in alzheimer’s disease. Alzheimers Dement. 2011;7(5):532–9. https://doi.org/10.1016/j.jalz.2011.05.2410
Maust DT, Strominger J, Kim HM, Langa KM, Bynum JPW, Chang CH, et al. Prevalence of central nervous system-active polypharmacy among older adults with dementia in the US. JAMA. 2021;325(10):952–61. https://doi.org/10.1001/jama.2021.1195
Gnjidic D, Hilmer SN, Hartikainen S, Tolppanen AM, Taipale H, Koponen M, et al. Impact of high risk drug use on hospitalization and mortality in older people with and without alzheimer’s disease: a national population cohort study. PLoS ONE. 2014;9(1):e83224. https://doi.org/10.1371/journal.pone.0083224
McMichael AJ, Zafeiridi E, Ryan M, Cunningham EL, Passmore AP, McGuinness B. Anticholinergic drug use and risk of mortality for people with dementia in Northern Ireland. Aging Ment Health. 2021;25(8):1475–82. https://doi.org/10.1080/13607863.2020.1830028
Barry HE, Cooper JA, Ryan C, Passmore AP, Robinson AL, Molloy GJ, et al. Potentially inappropriate prescribing among people with dementia in primary care: a retrospective cross-sectional study using the enhanced prescribing database. J Alzheimers Dis. 2016;52(4):1503–13. https://doi.org/10.3233/JAD-151177
Delgado J, Bowman K, Clare L. Potentially inappropriate prescribing in dementia: a state-of-the-art review since 2007. BMJ Open. 2020;10(1). https://doi.org/10.1136/bmjopen-2019-029172
Murphy C, Dyer AH, Lawlor B, Kennelly SP. Potentially inappropriate medication use in older adults with mild-moderate alzheimer’s disease: prevalence and associations with adverse events. Age Ageing. 2020;49(4):580–7. https://doi.org/10.1093/ageing/afaa067
Delgado J, Jones L, Bradley MC, Allan LM, Ballard C, Clare L, et al. Potentially inappropriate prescribing in dementia, multi-morbidity and incidence of adverse health outcomes. Age Ageing. 2021;50(2):457–64. https://doi.org/10.1093/ageing/afaa147
Liu AK, Possin KL, Cook KM, Lynch S, Dulaney S, Merrilees JJ, et al. Effect of collaborative dementia care on potentially inappropriate medication use: outcomes from the care ecosystem randomized clinical trial. Alzheimers Dement. 2022;10:1002. https://doi.org/10.1002/alz.12808
Al Odhayani A, Tourkmani A, Alshehri M, Alqahtani H, Mishriky A. Potentially inappropriate medications prescribed for elderly patients through family physicians. Saudi J Biol Sci. 2017;24(1):200–7. https://doi.org/10.1016/j.sjbs.2016.05.006
Jastaniah NA, Almaqati AS, Alsuraihi AK, Abughanim SA, Aseeri M. Inappropriate prescribing in elderly inpatients at a university hospital in Saudi Arabia. Drugs Real World Outcomes. 2018;5(4):211–6. https://doi.org/10.1007/s40801-018-0142-0
Alhawassi TM, Alatawi W, Alwhaibi M. Prevalence of potentially inappropriate medications use among older adults and risk factors using the 2015 American Geriatrics Society Beers criteria. BMC Geriatr. 2019;19(1):154. https://doi.org/10.1186/s12877-019-1168-1
Alturki A, Alaama T, Alomran Y, Al-Jedai A, Almudaiheem H, Watfa G. Potentially inappropriate medications in older patients based on Beers criteria: a cross-sectional study of a family medicine practice in Saudi Arabia. BJGP Open. 2020;4(1). https://doi.org/10.3399/bjgpopen20X101009
WHO Collaborating Centre for Drug Statistics Methodolgy. Guidelines for ATC classification and DDD assignment. 2022. Oslo, Norway; 2021.
IBM Corp. (2020) IBM SPSS Statistics for Windows VA, NY: IBM Corp. IBM SPSS statistics for windows. Armonk, NY: IBM Corp; 2020.
Renom-Guiteras A, Thürmann PA, Miralles R, Klaaßen-Mielke R, Thiem U, Stephan A, et al. Potentially inappropriate medication among people with dementia in eight European countries. Age Ageing. 2018;47(1):68–74. https://doi.org/10.1093/ageing/afx147
Bala SS, Jamieson HA, Nishtala PS. Determinants of prescribing potentially inappropriate medications in a nationwide cohort of community dwellers with dementia receiving a comprehensive geriatric assessment. Int J Geriatr Psychiatry. 2019;34(1):153–61. https://doi.org/10.1002/gps.5004
Balkhi B, AlQahtani N, Alwhaibi M, Alshammari TM, Alhawassi TM, Mahmoud MA, et al. Prevalence and factors associated with polypharmacy use among adult patients in Saudi Arabia. J Patient Saf. 2021;17(8):e1119–24. https://doi.org/10.1097/pts.0000000000000439
Parsons C, Johnston S, Mathie E, Baron N, Machen I, Amador S, et al. Potentially inappropriate prescribing in older people with dementia in care homes: a retrospective analysis. Drugs Aging. 2012;29(2):143–55. https://doi.org/10.2165/11598560-000000000-00000
Tommelein E, Mehuys E, Petrovic M, Somers A, Colin P, Boussery K. Potentially inappropriate prescribing in community-dwelling older people across Europe: a systematic literature review. Eur J Clin Pharmacol. 2015;71(12):1415–27. https://doi.org/10.1007/s00228-015-1954-4
Patel T, Slonim K, Lee L. Use of potentially inappropriate medications among ambulatory home-dwelling elderly patients with dementia: a review of the literature. Can Pharm J (Ott). 2017;150(3):169–83. https://doi.org/10.1177/1715163517701770
Ho SW, Teng YH, Yang SF, Yeh HW, Wang YH, Chou MC, et al. Association of proton pump inhibitors usage with risk of pneumonia in dementia patients. J Am Geriatr Soc. 2017;65(7):1441–7. https://doi.org/10.1111/jgs.14813
Kinoshita Y, Ishimura N, Ishihara S. Advantages and disadvantages of long-term proton pump inhibitor use. J Neurogastroenterol Motil. 2018;24(2):182–96. https://doi.org/10.5056/jnm18001
Jaynes M, Kumar AB. The risks of long-term use of proton pump inhibitors: a critical review. Ther Adv Drug Saf. 2019;10:2042098618809927. https://doi.org/10.1177/2042098618809927
Sura SD, Carnahan RM, Chen H, Aparasu RR. Prevalence and determinants of anticholinergic medication use in elderly dementia patients. Drugs Aging. 2013;30(10):837–44. https://doi.org/10.1007/s40266-013-0104-x
Welsh TJ, van der Wardt V, Ojo G, Gordon AL, Gladman JRF. Anticholinergic drug burden tools/scales and adverse outcomes in different clinical settings: a systematic review of reviews. Drugs Aging. 2018;35(6):523–38. https://doi.org/10.1007/s40266-018-0549-z
Ablett AD, Wood AD, Barr R, Guillot J, Black AJ, Macdonald HM, et al. A high anticholinergic burden is associated with a history of falls in the previous year in middle-aged women: findings from the Aberdeen prospective osteoporosis screening study. Ann Epidemiol. 2018;28(8):557–e622. https://doi.org/10.1016/j.annepidem.2018.05.011
Tan ECK, Eriksdotter M, Garcia-Ptacek S, Fastbom J, Johnell K. Anticholinergic burden and risk of stroke and death in people with different types of dementia. J Alzheimers Dis. 2018;65(2):589–96. https://doi.org/10.3233/jad-180353
Meraya AM, Banji OJF, Khobrani MA, Alhossan A. Evaluation of psychotropic medications use among elderly with psychitric disorders in Saudi Arabia. Saudi Pharm J. 2021;29(6):603–8. https://doi.org/10.1016/j.jsps.2021.04.021
Clyne B, Fitzgerald C, Quinlan A, Hardy C, Galvin R, Fahey T, et al. Interventions to address potentially inappropriate prescribing in community-dwelling older adults: a systematic review of randomized controlled trials. J Am Geriatr Soc. 2016;64(6):1210–22. https://doi.org/10.1111/jgs.14133
Campins L, Serra-Prat M, Gózalo I, López D, Palomera E, Agustí C, et al. Randomized controlled trial of an intervention to improve drug appropriateness in community-dwelling polymedicated elderly people. Fam Pract. 2017;34(1):36–42. https://doi.org/10.1093/fampra/cmw073
Martin P, Tamblyn R, Benedetti A, Ahmed S, Tannenbaum C. Effect of a pharmacist-led educational intervention on inappropriate medication prescriptions in older adults: the d-prescribe randomized clinical trial. JAMA. 2018;320(18):1889–98. https://doi.org/10.1001/jama.2018.16131
Reeve E, Trenaman SC, Rockwood K, Hilmer SN. Pharmacokinetic and pharmacodynamic alterations in older people with dementia. Expert Opin Drug Metab Toxicol. 2017;13(6):651–68. https://doi.org/10.1080/17425255.2017.1325873
Bloomfield HE, Greer N, Linsky AM, Bolduc J, Naidl T, Vardeny O, et al. Deprescribing for community-dwelling older adults: a systematic review and meta-analysis. J Gen Intern Med. 2020;35(11):3323–32. https://doi.org/10.1007/s11606-020-06089-2
Ie K, Aoshima S, Yabuki T, Albert SM. A narrative review of evidence to guide deprescribing among older adults. J Gen Fam Med. 2021;22(4):182–96. https://doi.org/10.1002/jgf2.464
McGrattan M, Ryan C, Barry HE, Hughes CM. Interventions to improve medicines management for people with dementia: a systematic review. Drugs Aging. 2017;34(12):907–16. https://doi.org/10.1007/s40266-017-0505-3
Shafiee Hanjani L, Long D, Peel NM, Peeters G, Freeman CR, Hubbard RE. Interventions to optimise prescribing in older people with dementia: a systematic review. Drugs Aging. 2019;36(3):247–67. https://doi.org/10.1007/s40266-018-0620-9
Sawan MJ, Moga DC, Ma MJ, Ng JC, Johnell K, Gnjidic D. The value of deprescribing in older adults with dementia: a narrative review. Expert Rev Clin Pharmacol. 2021;14(11):1367–82. https://doi.org/10.1080/17512433.2021.1961576
Aljawadi MH, Khoja AT, Alaboud NM, AlEnazi ME, Al-Shammari SA, Khoja TA, et al. Prevalence of polypharmacy and factors associated with it among Saudi older adults - results from the Saudi national survey for elderly health (SNSEH). Saudi Pharm J. 2022;30(3):230–6. https://doi.org/10.1016/j.jsps.2022.01.003
Earl TR, Katapodis ND, Schneiderman SR, Shoemaker-Hunt SJ. Using deprescribing practices and the screening tool of older persons’ potentially inappropriate prescriptions criteria to reduce harm and preventable adverse drug events in older adults. J Patient Saf. 2020;16(1):S23–35. https://doi.org/10.1097/pts.0000000000000747
Acknowledgements
The authors wish to thank King Saud University Medical City (KSUMC) for allowing us to conduct this study in the medical city and providing access to the data.
Funding
Nahla A. Alageel is supported by a PhD Scholarship from King Saud University, Saudi Arabia. The funder played no role in the design, analysis or conduct of the study.
Author information
Authors and Affiliations
Contributions
All authors contributed to the conception and design of the study. NA performed data collection and data analysis with advice from HB, CH and MA. WA provided additional clinical input and critical review of emergent findings. NA drafted the manuscript. All authors reviewed the manuscript, actively contributed to revising it, and approved the final version.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
The study was approved by the Institutional Review Board of King Saud University (reference number E-21-6288). All methods were carried out in accordance with relevant guidelines and regulations. The requirement for individual informed consent was formally waived by the Institutional Review Board of King Saud University because of the retrospective nature of this study and all date were anonymised before analysis.
Consent for publication
Not applicable.
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Alageel, N.A., Hughes, C.M., Alwhaibi, M. et al. Potentially inappropriate prescribing for people with dementia in ambulatory care: a cross-sectional observational study. BMC Geriatr 24, 328 (2024). https://doi.org/10.1186/s12877-024-04949-8
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s12877-024-04949-8